Eli Lilly and Company Announces Detailed Results from Triumph-2 Phase 3 Trial Evaluating Retatrutide in Adults with Type 2 Diabetes and Obesity or Overweight

Eli Lilly (LLY) received FDA Breakthrough Therapy designation for olomorasib, a KRAS G12C inhibitor, for advanced pancreatic cancer. The designation may accelerate development and focus resources on oncology. CEO David Ricks also expressed interest in larger acquisitions in areas like infectious disease and psychiatric conditions. Eli Lilly is a global pharmaceutical company with a market cap of US$1.1b.

Eli Lilly's experimental drug retatrutide showed significant weight loss in two studies. Patients with type 2 diabetes lost 18.8% of body weight, while non-diabetic participants lost 25%. The company plans FDA approval submission in 2027.

Eli Lilly's obesity drug retatrutide showed promising results in a late-stage trial, with participants losing up to 25% of their weight. The drug also reduced knee pain and sleep apnea events. Eli Lilly is developing the drug, which targets GLP-1, GIP, and glucagon. The trial did not compare it to existing treatments, and further studies are needed to assess safety and efficacy. According to the trial data, more than a third of participants lost 30% or more of their weight.

Eli Lilly (LLY) reported positive Phase 3 trial results for retatrutide, showing significant weight loss and improved glycemic control in type 2 diabetes patients. The company plans an FDA submission by Q1 2027. LLY's stock is modestly undervalued, with a GF Value™ of $1,559.98, 24.1% above its current price of $1,184.63. The GF Score™ is 96/100, indicating strong financial health and growth.

Eli Lilly reported that its experimental drug helped adults with type 2 diabetes and obesity lose an average of 21% of their body weight in a late-stage clinical trial.

Eli Lilly's retatrutide helped Type 2 diabetes patients lose up to 60 lbs (23% body weight) in trials, published in The Lancet. It outperformed competitors like semaglutide and tirzepatide. The drug, a 'triple agonist,' mimics three hormones. Lilly plans FDA approval filing early next year. Side effects included diarrhea and nausea. Experts note potential for diabetes remission but caution about strength for some patients.